SU5416, a receptor tyrosine kinase inhibitor, is active in preclinical models of acute myeloid leukemia.

被引：0
|
作者：
Bertolini, F
Dell'Agnola, C
Gobbi, A
Monestiroli, S
Pruneri, G
McMahon, G
Martinelli, G
机构：
[1] European Inst Oncl, Milan, Italy
[2] Sugen Inc, San Francisco, CA USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
505
引用
收藏
页码：117A / 117A
页数：1
相关论文
共 50 条
  • [41] SU5416 and SU6668 inhibit biological functions of c-kit in a myeloid leukemia cell line and in AML blasts.
    Smolich, BD
    Yuen, HA
    West, KA
    Giles, FJ
    Albitar, M
    Cherrington, JM
    CLINICAL CANCER RESEARCH, 2000, 6 : 4519S - 4519S
  • [42] SU5416: A potent and selective Flk-1/KDR kinase inhibitor that blocks receptor autophosphorylation, endothelial cell mitogenesis, and tumor growth
    Tang, C
    Li, S
    Tran, J
    Liang, C
    Nematalla, A
    Fong, A
    App, H
    Rice, A
    Kim, Y
    Schreck, R
    Chen, J
    Dowd, B
    Suto, E
    Vasile, S
    Shawver, L
    McMahon, J
    Hirth, P
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1998, 215 : U920 - U920
  • [43] Acute cardiotoxicity after initiation of the novel tyrosine kinase inhibitor gilteritinib for acute myeloid leukemia
    Lisa Kim
    Brian Fowler
    Courtney M. Campbell
    Jeremy Slivnick
    Haseeb Nawaz
    Yaquta Kaka
    Patrick Ruz
    Ajay Vallakati
    Ragavendra Baliga
    Sumithira Vasu
    Daniel Addison
    Cardio-Oncology, 7
  • [44] Acute cardiotoxicity after initiation of the novel tyrosine kinase inhibitor gilteritinib for acute myeloid leukemia
    Kim, Lisa
    Fowler, Brian
    Campbell, Courtney M.
    Slivnick, Jeremy
    Nawaz, Haseeb
    Kaka, Yaquta
    Ruz, Patrick
    Vallakati, Ajay
    Baliga, Ragavendra
    Vasu, Sumithira
    Addison, Daniel
    CARDIO-ONCOLOGY, 2021, 7 (01)
  • [45] MER RECEPTOR TYROSINE KINASE AS A POTENTIAL NOVEL TARGET IN ACUTE MYELOID LEUKEMIA
    Eisenman, Kristen
    Sather, Susan
    McGranahan, Amy
    Liang, Xiayaun
    Desch, Ashley
    Cannon, Cara
    Martinson, Hollie
    Keating, Amy
    Graham, Doug
    PEDIATRIC BLOOD & CANCER, 2010, 54 (06) : 790 - 790
  • [46] Mer Receptor Tyrosine Kinase Is A Potential Therapeutic Target in Acute Myeloid Leukemia
    Lee-Sherick, Alisa B.
    Menachof, Kelly
    Eisenman, Kristen M.
    McGranahan, Amy
    McGary, Colleen
    Hunsucker, Sally A.
    Schlegel, Jennifer
    Armistead, Paul M.
    Liang, Xiayuan
    Kireev, Dmitri
    Janzen, William
    Liu, Jing
    Stashko, Michael
    Norris-Drouin, Jacqueline
    Earp, H. Shelton, III
    Wang, Xiaodong
    Frye, Stephen
    DeRyckere, Deborah
    Graham, Douglas K.
    BLOOD, 2012, 120 (21)
  • [47] DISCONTINUATION OF TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA. EXPERIENCE IN A CENTER
    Navarro-Almenzar, Begona
    Perez, Lopez Raul
    Fernandez, Poveda Elena
    Leal, Rubio Juan Diego
    Sanchez, Villalobos Maria
    Serrano, Jara Claudia
    HAEMATOLOGICA, 2020, 105 : 394 - 395
  • [48] Flk-1 specific kinase inhibitor SU5416 blocked angiogenesis of Lewis carcinoma in mouse and prolonged the survival
    Yizhou Luo1
    Chinese-German Journal of Clinical Oncology, 2008, (07) : 420 - 423
  • [49] Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
    Goldman, JM
    Melo, JV
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14): : 1084 - 1086
  • [50] SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
    Fong, TAT
    Shawver, LK
    Sun, L
    Tang, C
    App, H
    Powell, TJ
    Kim, YH
    Schreck, R
    Wang, XY
    Risau, W
    Ullrich, A
    Hirth, KP
    McMahon, G
    CANCER RESEARCH, 1999, 59 (01) : 99 - 106
12345